Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Winter;18(4):485-492.
doi: 10.22074/cellj.2016.4715. Epub 2016 Sep 26.

A Brief Review on The Molecular Basis of Medullary Thyroid Carcinoma

Affiliations
Review

A Brief Review on The Molecular Basis of Medullary Thyroid Carcinoma

Masoumeh Mohammadi et al. Cell J. 2017 Winter.

Abstract

Approximately 5-10% of all thyroid cancers are medullary thyroid carcinomas (MTC). MTC is mainly sporadic in nature, but 20-30% of cases are hereditary. Genetic testing for hereditary MTC is very important for the patient and his family, but the patients must be receiving appropriate genetic counseling. About 98% of patients with hereditary MTC have germline mutations in exons 10, 11, 13, 14, 15, 16 and intron 16 of the REarrangement during transfection (RET) proto-oncogene, but the etiology of the more frequent sporadic form of MTC (sMTC) is not well understood. Recently, it has been reported that apparently sporadic MTC may involve point mutations in BRAF and RAS genes, with an overall prevalence of almost 10%. Also alteration and abnormal expression of miRNA has been described in MTC. In this review, we attempted to mention some mutations and molecular changes in sporadic and hereditary MTC pathogenesis.

Keywords: Medullary Thyroid Carcinoma; RET Proto-Oncogene; miRNA.

PubMed Disclaimer

Figures

Fig.1
Fig.1
REarrangement during transfection (RET) structure. RET protein composed a cytoplasmic tyrosine kinase domain, a transmembrane domain, and cysteine rich domain.
Fig.2
Fig.2
RET signaling. RET signaling leads to the activation of the RAS/MAPK and the PI3K/Akt pathways. RET; REarranged during transfection, MAPK; Mitogen-activated protein kinase, BRAF; Proto-oncogene B-Raf, MEK; Is a member of the MAPK signaling cascade, ERK; Extracellular signal-regulated kinases, PI3K; Phosphatidylinositol 3′ kinase, AKT; Is an oncogene that encode serine/threonine-protein kinase, and mTOR; Mechanistic target of rapamycin.
Fig.3
Fig.3
MicroRNA genes are transcribed by RNA polymerase II as pri-microRNA that is processed by a protein complex containing the RNase III enzyme, to form pre-microRNA. Pre-microRNA is processed by a second RNase III enzyme (DICER) to form a mature microRNA with approximately 20-22 nucleotides. The mature microRNAs with ribonuclear particles are incorporated to form the RNA induced silencing complex (RISC) which mediates gene silencing.

References

    1. DeLellis RA. Pathology and genetics of thyroid carcinoma. J Surg Oncol. 2006;94(8):662–669. - PubMed
    1. Sippel RS, Kunnimalaiyaan M, Chen H. Current management of medullary thyroid cancer. Oncologist. 2008;13(5):539–547. - PubMed
    1. Clark OH. Controversies in familial thyroid cancer 2014. Ulus Cerrahi Derg. 2014;30(2):62–66. - PMC - PubMed
    1. A T, F S, G P, M B. Genetic alterations in medullary thyroid cancer: diagnostic and prognostic markers. Curr Genomics. 2011;12(8):618–625. - PMC - PubMed
    1. Griebeler ML, Gharib H, Thomson GB. Medullary thyroid carcinoma. Endocr Pract. 2013;19(4):703–711. - PubMed

LinkOut - more resources